BW Offshore
15.3.2021 20:01:34 CET | Globenewswire | Press release
Completion of BW Ideol transactions
Reference is made to stock exchange announcement made by BW Offshore Limited on 17 February 2021 regarding the investment in Ideol S.A. creating BW Ideol AS (the "Transaction").
After obtaining regulatory approval and following satisfaction of other conditions, BW Ideol AS today completed the share purchase agreement and acquired Ideol S.A. The agreed funds have been transferred to the selling shareholders of Ideol S.A. who have sold their shares for cash and BW Ideol AS will issue a total of 5,815,240 shares to the sellers who have elected to contribute their shares in Ideol S.A. for shares in BW Ideol AS, following registration of the share capital increase in the Norwegian Register of Business Enterprises.
Following the above-mentioned completion, BW Ideol holds 100% of the shares outstanding in Ideol S.A.
For further information, please contact:
Anders S. Platou, Head of Corporate Finance, +47 99 50 47 40
IR@bwoffshore.com or www.bwoffshore.com
About BW Offshore:
BW Offshore engineers innovative floating production solutions. The Company has a fleet of 15 FPSOs with potential and ambition to grow. By leveraging four decades of offshore operations and project execution, the Company creates tailored energy solutions for evolving markets world-wide. BW Offshore has around 2,000 employees and is publicly listed on the Oslo Stock Exchange.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Una Holmen, Manager IR, BW Offshore on 15 March at 20.00.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Rocket Lab Corporation28.3.2026 11:39:53 CET | Press release
Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency
Vivoryon Therapeutics N.V.28.3.2026 07:00:00 CET | Press release
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
